The Edit review: $209 sema, $309 tirzepatide

The Edit (theedithealth.com) is the rare GLP-1 desk whose pricing page and product pages say the same thing. We read both in August 2026 and they agree line for line: same monthly rate, same prepay rungs, same terms, no drift between the page that sells and the page that discloses. That is not a low bar in this market — it is a bar most desks miss.

The standing rate is $209, not $109

Semaglutide is $209 a month. Tirzepatide is $309 a month. Those are the month-to-month rates, with no membership fee stacked on top and no minimum term, and they are what you pay from month two onward.¹ The $109 and $209 figures the site leads with are a $100-off first-order promotion — disclosed as one, right beside the standing rate, but a first-month number all the same. It is the teaser rate in its most honest form. It is still a teaser rate, and $209 is the number to budget on.

The prepay math actually works

Three months of semaglutide is $575 billed once; six months is $1,065. Divide those out and you get $191.67 and $177.50 a month — the site rounds to $192 and $178 and labels both rungs "billed once at the start of the plan". Tirzepatide is $855 for three months ($285 a month) and $1,575 for six ($262.50, printed as $263). Every division lands where it should.

That reads like faint praise. It is not. The most common pricing error this wire corrects is a prepay rung printed as if it were a monthly rate — a number nobody can buy for one month, sitting at the top of a cheapest-first ranking. The Edit does not do it. Both columns are labeled, the billing cadence is stated, and the monthly rung is the one shown first. Anyone building a semaglutide price comparison can take these figures at face value.

The rest of the shelf

Six prescription protocols, five injectable and one cream: semaglutide, tirzepatide, NAD+ at $249 a month, glutathione at $199, sermorelin at $169, and GHK-Cu cream at $129.¹ There is no oral GLP-1, no nasal line, no peptide sampler, and the site states outright that it does not sell research-use-only compounds. That last line is worth more than it looks: several desks in this cohort quietly stock compounds with no approval anywhere, retatrutide chief among them, and The Edit's catalog simply does not contain them.

Who is actually behind it

The corporate entity is The Edit Health LLC, a Texas management services organization in Austin. The medicine is practiced by Arora Health & Aesthetics, LLC, whose medical director is Dr. Sean Arora — NPI 1841729449, which we checked live against the federal NPPES registry and found active, family medicine, Seattle.² The pharmacy is The Pharmacy Hub, named on the site rather than described as "our pharmacy partner". The intake and billing run on Bask Health.

Naming both the prescriber and the pharmacy puts The Edit ahead of most of the desks we read this month, and it is the second and third item on our own five-minute provider checklist for a reason: a desk that will not tell you who writes the script or who compounds the drug has decided that you do not need to know.

One overlap you should know about

Dr. Arora and Arora Health & Aesthetics also stand behind Trellis Vitality, a separate brand with a different pharmacy, a different price ladder and a different catalog. The two are genuinely separable products. They are not two independent clinical opinions, and if you are weighing them against each other as alternatives, you are weighing the same prescriber twice.

Fees, refunds and the exit

Nothing is charged to start — the site says there is no charge and no card on file to begin, and a full refund is issued if a clinician does not approve you. A visit fee becomes non-refundable once a visit has actually happened, but none is taken up front, so there is no charge-regardless-of-outcome trap here. Compounded prescriptions are final sale once shipped, which is standard. Membership cancels at the end of the current period with no pro-rating, under a cancellation policy dated July 2026. The terms and help center both claim all 50 states, with address-level eligibility confirmed at the consultation — see how telehealth prescribing rules vary for why that last step exists.

The Spanish site is real

The Edit ships a complete Spanish mirror at /es/ — 33 Spanish URLs in its own sitemap, covering every page rather than a translated landing page and a dead end. Across the seven desks we researched in this batch, it is the only one with any Spanish surface at all.

What we could not check

We could not reach a checkout price. The Bask intake requires walking a questionnaire, and the JavaScript it loads carries framework code with no price table in it. So the ladder above is the published ladder, corroborated across two independent surfaces on the marketing site — not a figure confirmed at a card form. We say so rather than implying a stronger source than we have.

The regulatory screen

The trading name, the legal entity, the medical group and the named pharmacy all returned zero company-column matches in the FDA's live warning-letter index in August 2026.³ The same pass carried a positive control — an unrelated telehealth seller with a real February 2026 letter — and it returned correctly every time, so the zero here is a result rather than a query that quietly failed.

Where it lands

The Edit is not cheap. At $209 and $309 it sits in the upper half of the rates on our semaglutide and tirzepatide wires, and if price is the only thing you are optimizing, Pepti at $99 and Trellis at $150 both undercut it heavily. What you are buying at the higher number is a price surface with nothing hidden in it, a named pharmacy, a verifiable prescriber and an exit you can take at the end of any month. Read it against the rest of the evidence library before you decide which of those you are actually paying for.